A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib

References

• Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res. 2012;2:44–56.22432087
   PubMedGoogle Scholar
• Kazlauskas A. PDGFs and their receptors. Gene. 2017;614:1–7. doi:10.1016/j.gene.2017.03.00328267575
   PubMed Web of Science ®Google Scholar
• Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307–316. doi:10.1016/0092-8674(94)90322-08168137
   PubMed Web of Science ®Google Scholar
• Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123:3574–3577. doi:10.1182/blood-2014-02-55560724687085
   PubMed Web of Science ®Google Scholar
• Vega F, Medeiros LJ, Bueso-Ramos CE, et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144:377–392. doi:10.1309/AJCPMORR5Z2IKCEM26276769
   PubMed Web of Science ®Google Scholar
• Appiah-Kubi K, Lan T, Wang Y, et al. Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies. Crit Rev Oncol Hematol. 2017;109:20–34. doi:10.1016/j.critrevonc.2016.11.00828010895
   PubMed Web of Science ®Google Scholar
• Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96:1463–1470. doi:10.1007/s00277-017-3067-x28725989
   PubMed Web of Science ®Google Scholar
• Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704–714. doi:10.1182/blood-2016-10-69597328028030
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010;95:696–698. doi:10.3324/haematol.2009.02167520442440
   PubMed Web of Science ®Google Scholar
• Morerio C, Acquila M, Rosanda C, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004;64:2649–2651. doi:10.1158/0008-5472.CAN-03-402615087372
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Orazi A, Kelemen K, et al. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021;155:160–178. doi:10.1093/ajcp/aqaa20833367495
   PubMed Web of Science ®Google Scholar
• Arefi M, Garcia JL, Penarrubia MJ, et al. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur J Haematol. 2012;89:37–41. doi:10.1111/j.1600-0609.2012.01799.x22587685
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Schwaab J, Gosenca D, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27:2254–2256. doi:10.1038/leu.2013.12923615556
   PubMed Web of Science ®Google Scholar
• David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007;109:61–64. doi:10.1182/blood-2006-05-02482816960151
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Maruoka H, Ishikawa T. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia. Int J Hematol. 2017;105:697–701. doi:10.1007/s12185-016-2167-z28000100
   PubMed Web of Science ®Google Scholar
• Bell GC, Padron E. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: a case for broad spectrum tumor profiling. Leuk Res Rep. 2015;4:70–71.26716078
   PubMedGoogle Scholar
• Wenger TL, Bly RA, Wu N, et al. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020;182:1576–1591. doi:10.1002/ajmg.a.6161532500973
   PubMed Web of Science ®Google Scholar
• Naymagon L, Marcellino B, Mascarenhas J. Eosinophilia in acute myeloid leukemia: overlooked and underexamined. Blood Rev. 2019;36:23–31. doi:10.1016/j.blre.2019.03.00730948162
   PubMed Web of Science ®Google Scholar
• Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 2008;3:e3794. doi:10.1371/journal.pone.000379419030102
   PubMed Web of Science ®Google Scholar
• Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007;117:730–738. doi:10.1172/JCI2898417290308
   PubMed Web of Science ®Google Scholar
• Tokita K, Maki K, Tadokoro J, et al. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia. 2007;21:190–192. doi:10.1038/sj.leu.240439717122866
   PubMed Web of Science ®Google Scholar
• Byrgazov K, Kastner R, Gorna M, et al. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2017;31:237–240. doi:10.1038/leu.2016.25027573554
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao Y, Zhang H, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018;131:2256–2261. doi:10.1182/blood-2017-11-81751029434033
   PubMed Web of Science ®Google Scholar
• Tran TH, Nguyen JV, Stecula A, et al. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021. doi:10.3324/haematol.2020.261354
   Web of Science ®Google Scholar